Weight Gain Associated With Olanzapine and Risperidone in Adolescent Patients: A Comparative Prospective Study

Ratzoni, Gidi; Gothelf, Doron; Brand-Gothelf, Ayelet; Reidman, Judith; Kikinzon, Leonid; Gal, Gilad; Phillip, Moshe; Apter, Alan; Weizman, Ronit

doi:10.1097/00004583-200203000-00014

Cited by 216 publications

(115 citation statements)

References 31 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Shorter-term trials indicate that a large proportion of the antipsychotic-induced weight gain may occur early in treatment. Ratzoni et al (2002) for example, have shown significant weight gain of first-episode psychosis patient treated with olanzapine (+7.2 kg), risperidone (+3.9 kg) but not for haloperidol (+1.1 kg) while in psychiatric inpatient treatment, thus keeping environmental influences such as differences in diet and physical exercise to a minimum. Evidence for the assumption that a large proportion of weight gain occurs early in treatment is provided by observations that the weight gain may, after various time periods, level off (Kinon et al, 2001;Henderson et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis

Strassnig

Miewald

Keshavan

et al. 2007

Schizophrenia Research

112

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis

Strassnig

Miewald

Keshavan

et al. 2007

Schizophrenia Research

112

View full text Add to dashboard Cite

“…Most clinical studies found male patients treated with atypical antipsychotics to be at higher risk for weight gain than female patients. [26][27][28] However, one study reported female patients to be at higher risk 29 . The different risk for weight gain could in part be explained by hormonal differences and differential interaction of the hormones with receptors including DRD4.…”

Section: Discussionmentioning

confidence: 99%

DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain

et al. 2008

View full text Add to dashboard Cite

Weight gain is a major side effect of antipsychotic treatment. The antidopaminergic and antiserotonergic effect of antipsychotics may contribute to antipsychotic-induced weight gain. We, therefore conducted a prospective clinical study, to investigate whether the D4 receptor (DRD4) 48 bp (base pair) variable number of tandem repeat (VNTR) polymorphism and the 5-hydroxytryptamine 2C receptor (HT 2C ) cysteine for serine substitution at position 23 (Cys23Ser) polymorphism may influence weight gain during antipsychotic treatment in a naturalistic setting of 102 Caucasian psychiatric in-patients. Patients suffering from psychotic disorders and treated according to local clinical practice were classified as either homozygous for the shorter alleles of the DRD4 48 bp VNTR polymorphism (o7-fold repeat, group 1) or heterozygous/homozygous for the long allele (7-fold repeat or higher, group 2). HT 2C Cys23Ser polymorphism male patients were grouped hemizygous G (Cys) or C (Ser), while female patients were GG, GC or CC and both sexes were evaluated separately. Concerning the DRD4 48 bp VNTR polymorphism the increase in body mass index was significantly less in group 1 (0.38 kg m À2 ; s.d. ¼ 1.04) than in group 2 (0.89 kg m À2 ; s.d. ¼ 1.23; P ¼ 0.003). The difference between the genotype groups remained significant in male patients but not in female patients. In contrast, no influence on antipsychotic-induced increase in body weight was observed for the HT 2C Cys23Ser polymorphism. These results support the hypothesis that the DRD4 48 bp VNTR polymorphism influences antipsychotic-induced weight gain. Male patients may be more affected than female patients. Due to the limitations of the study (heterogeneity of treatment, pretreatment and concomitant therapy) further studies are required before diagnostic genotyping of the DRD4 48 bp VNTR polymorphism may be useful for individualizing therapy.

show abstract

“…[114][115][116] Possibly significant side effects, such as elevation of prolactin and triglyceride (risperidone, quetiapine and olanzapine) levels, a greater risk for type 2 diabetes (olanzapine and possibly other atypical antipsychotics), and long QT syndrome (ziprasidone) require that these patients be carefully monitored. [117][118][119] Clomipramine (tricyclic antidepressant and nonselective serotonin reuptake blocker) proved to be efficient in the treatment of obsessive-compulsive behavior and, more recently, in obsessive-compulsive symptoms, in the minimization of stereotypies and self-injurious behavior in autistic patients. The risk of cardiac arrhythmias, among others, has restricted its use.…”

Section: Pharmacotherapymentioning

confidence: 99%

Autismo e doenças invasivas de desenvolvimento

Gadia¹,

Tuchman²,

Rotta³

2004

J. Pediatr. (Rio J.)

119

View full text Add to dashboard Cite

Objective: To review the current knowledge on neurobiological aspects of autism and pervasive developmental disorders, as well as to provide pediatricians with up to date information on diagnosis and treatment of autism. Sources of data: Review of MEDLINE and Internet.Summary of the findings: Autism is the 3rd developmental disorder, with an incidence of 40 to 130/100,000 individuals. Diagnosis is based on clinical findings, following DSM IV criteria. Neuroimaging, investigation of fetal neurological status, and genetic investigation contribute towards a better understanding of the neurobiology of autism. Conclusion:Pediatricians are the first health professional to come in contact with patients with autism. Thus, they should be able to diagnose and to coordinate the multidisciplinary treatment of these patients.J Pediatr (Rio J). 2004;80(2 Suppl):S83-S94: Autism, child behavior, child development.

show abstract

Weight Gain Associated With Olanzapine and Risperidone in Adolescent Patients: A Comparative Prospective Study

Cited by 216 publications

References 31 publications

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis

DRD4 48 bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain

Autismo e doenças invasivas de desenvolvimento

Contact Info

Product

Resources

About